We are monitoring the impact of COVID-19 on Europe Liver Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 780
Share on
Share on

Europe Liver Cancer Therapeutics Market Research Report - Segmented By Type, Therapeutics, End-User and Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends and Forecast | 2019 - 2024

Pulished: August, 2019
ID: 780
Pages: 145

Europe Liver Cancer Therapeutics Market Size & Growth (2019 - 2024)

The size of the Liver Cancer Therapeutics Market in Europe was worth USD 170.21 million in 2019 and estimated to be growing at a CAGR of 8.89%, to reach USD 260.57 million by 2024.

Europe's lung cancer diagnostics and therapeutics market will continue to avail favorable growth over the next few years. Invention and new product launches by the current as well as the new market players is the key factor projected to drive this market.

Studies on liver cancer therapeutics illustrate that the prevalence of liver cancer is greater in men than in women and is generally seen in people over the age of 50. Treatment is based on tumor size, location, and overall health. A most common type of liver cancer HCC is often unresectable, meaning that it cannot be removed surgically.

Factors such as increasing elderly population across the region, growing population base of cancer patients, technological developments in treatment and diagnosis procedures, rising number of hospitals and surgical centers and growing demand for minimally invasive cancer treatment techniques are driving the growth of the liver cancer therapeutics market.

However, the high cost involved in the diagnosis, as well as treatment procedures of cancer, is acting as a major restraint for the market.

This research report segmented and sub-segmented into the following categories:

  • By Type: Primary, Secondary and Benign Liver Growths
  • By Therapeutics: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma and Targeted Therapy
  • By End-User: Pediatrics and Adults
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

On the basis of therapeutics, the Hepatocellular Carcinoma is the largest segment for therapeutics type due to the high prevalence of this type of liver cancer among people.

Regionally, the U.K and Germany are estimated to be the leading markets in this region while France is anticipated to witness the highest growth in the forecast period.

Key players operating in the Europe Liver Cancer Therapeutics Market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Primary    

                             5.1.2 Secondary             

                             5.1.3 Benign Liver growths         

              5.2 By Therapeutics                     

                             5.2.1 Hepatocellular Carcinoma

                             5.2.2 Cholangio carcinoma        

                             5.2.3 Hepatoblastoma  

                             5.2.4 Targeted Therapy

              5.3 By End-Users                          

                             5.3.1 Pediatrics

                             5.3.2 Adults      

6. Geographical Analysis                                         

                             6.1 Introduction             

                             6.2 U.K 

                             6.3 Spain           

                             6.4 Germany    

                             6.5 Italy             

                             6.6 France         

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Alnylam Pharmaceuticals Inc.                          

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 ImClone Systems Inc.                          

              9.3 Onyx Pharmaceuticals Inc.                 

              9.4 F. Hoffmann-La Roche Ltd.                

              9.5 Pfizer Inc.                  

              9.6 ArQule Inc.               

              9.7 Jennerex Biotherapeutics Inc.                         

              9.8 Celsion Corp.                          

              9.9 Bayer Schering Pharma AG                

              9.10 4SC AG                    

              9.11 Bristol-Myers Squibb Company                    

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Liver Cancer Diagnostics and Therapeutics Market By Region, From 2019-2024 (USD Million)
  2. Europe Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  3. Europe Primary Market By Region, From 2019-2024 (USD Million)
  4. Europe Secondary Market By Region, From 2019-2024 (USD Million)
  5. Europe Benign Liver growths Market By Region, From 2019-2024 (USD Million)
  6. Europe Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  7. Europe Hepatocellular Carcinoma Market By Region, From 2019-2024 (USD Million)
  8. Europe Cholangio carcinoma Market By Region, From 2019-2024 (USD Million)
  9. Europe Hepatoblastoma Market By Region, From 2019-2024 (USD Million)
  10. Europe Targeted Therapy Market By Region, From 2019-2024 (USD Million)
  11. Europe Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  12. Europe Pediatrics Market By Region, From 2019-2024 (USD Million)
  13. Europe Adults Market By Region, From 2019-2024 (USD Million)
  14. U.K Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  15. U.K Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  16. U.K Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  17. Spain Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  18. Spain Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  19. Spain Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  20. Germany Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  21. Germany Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  22. Germany Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  23. Italy Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  24. Italy Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  25. Italy Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)
  26. France Liver Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Million)
  27. France Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2019-2024 (USD Million)
  28. France Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2019-2024 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample